CARL NASDAQ
Carlsmed, Inc.
1W: +17.6%
1M: +19.1%
3M: -0.9%
YTD: +8.8%
$12.11
-0.54 (-4.27%)
Weekly Expected Move ±9.5%
$9
$10
$11
$12
$13
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (28)
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
Wall Street Analysts Think Carlsmed, Inc. (CARL) Could Surge 90.77%: Read This Before Placing a Bet
Carlsmed raises FY 2026 revenue outlook to $72M-$77M as CMS proposes new MS-DRGs for aprevo lumbar
Carlsmed, Inc. (CARL) Reports Q1 Loss, Tops Revenue Estimates
Carlsmed, Inc. GAAP EPS of -$0.32, revenue of $16.1M
Carlsmed (CARL) Q1 2026 Earnings Transcript
Carlsmed Q1 2026 Earnings Call: Complete Transcript
Carlsmed® Reports First Quarter 2026 Financial Results
Carlsmed® Reports First Quarter 2026 Financial Results
Earnings Scheduled For May 5, 2026
Analysts Set Carlsmed, Inc. (NASDAQ:CARL) PT at $19.67
Brokerages Set Carlsmed, Inc. (NASDAQ:CARL) PT at $21.33
Brokerages Set Carlsmed, Inc. (NASDAQ:CARL) Target Price at $21.33
Carlsmed, Inc. GAAP EPS of -$0.32 beats by $0.11, revenue of $15.2M beats by $0.34M
Carlsmed targets $70M–$75M 2026 revenue with cervical and bilateral product launches amid 44% growth outlook
Carlsmed, Inc. (CARL) Q4 2025 Earnings Call Transcript
Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results
Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference
Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Procedure
Carlsmed (NASDAQ:CARL) & Profusa (NASDAQ:PFSA) Financial Survey
Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
Carlsmed, Inc.’s Lock-Up Period Set To End on January 19th (NASDAQ:CARL)
Carlsmed aprevo® Lumbar 2-year Data Published in Global Spine Journal
Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare Conference
CARL Launches Aprevo Cervical Platform for Personalized Spine Surgery
Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting
Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference